Immunosuppression for acquired hemophilia A: Results from the European Acquired Haemophilia Registry (EACH2)

Blood

Volumn 120, Issue 1, 2012, Pages 47-55

  Collins, Peter ^a   Baudo, Francesco ^b   Knoebl, Paul ^c   Lévesque, Hervé ^d   Nemes, László ^e   Pellegrini, Fabio ^f   Marco, Pascual ^g   Tengborn, Lilian ^h   Huth Kühne, Angela ⁱ  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d ROUEN UNIVERSITY HOSPITAL   (France)

^e State Health Center   (Hungary)

^f Consorzio Mario Negri Sud ^*  (Italy)

^g HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^h LUND UNIVERSITY HOSPITAL   (Sweden)

ⁱ Department of Internal Medicine   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC AGENT; DEXAMETHASONE; IMMUNOGLOBULIN; PREDNISONE; RITUXIMAB; STEROID;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COMPARATIVE EFFECTIVENESS; DIABETES MELLITUS; DRUG TREATMENT FAILURE; FEMALE; HEMOPHILIA A; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NEUTROPENIA; POST TREATMENT SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; REMISSION; SCHOOL CHILD; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84863538386     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-02-409185     Document Type: Article

References (23)

1. Collins PW. Management of acquired haemophilia A. J Thromb Haemost. 2011;9(Suppl 1):226-235.
2. Green D, Lechner K.Asurvey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost. 1981;45(3):200-203. (Pubitemid 11081028)
3. Kessler CM, Asatiani E. Acquired inhibitors to factor VIII. In: Lee CA, Berntorp EE, Hoots WK, Aledort LM, eds. Textbook of Hemophilia. Oxford, United Kingdom: Wiley; 2007:86-90.
4. Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol. 2003;121(1):21-35. (Pubitemid 36461264)
5. Collins PW, Hirsch S, Baglin TP, et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood. 2007;109(5):1870-1877. (Pubitemid 46348182)
6. Morrison AE, Ludlam CA. Acquired haemophilia and its management. Br J Haematol. 1995;89(2):231-236.
7. Lottenberg R, Kentro TB, Kitchens CS. Acquired hemophilia: a natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch Intern Med. 1987;147(6):1077-1081. (Pubitemid 17113272)
8. Hay CR, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol. 2006;133(6):591-605. (Pubitemid 43742773)
9. Huth-Kühne A, Baudo F, Collins P, et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica. 2009;94(4):566-575.
10. Boles JC, Key NS, Kasthuri R, Ma AD. Single-center experience with rituximab as first-line immunosuppression for acquired hemophilia. J Thromb Haemost. 2011;9(7):1429-1431.
11. Franchini M, Lippi G. Acquired factor VIII inhibitors. Blood. 2008;112(2):250-255.
12. Stasi R, Brunetti M, Stipa E, Amadori S. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood. 2004;103(12):4424-4428. (Pubitemid 38745966)
13. Baudo F, de Cataldo F. Acquired haemophilia in the elderly. In: Balducci L, Ershler W, de Gaetano G, eds. Blood Disorders in the Elderly. Cambridge, United Kingdom: Cambridge University Press; 2007:389-407.
14. Knoebl P, Marco P, Baudo F, et al. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost. 2012;10(4):622-631.
15. Green D, Rademaker AW, Briet E. A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies. Thromb Haemost. 1993;70(5):753-757. (Pubitemid 23339447)
16. Baudo F, de Cataldo F. Acquired factor VIII inhibitors in pregnancy: data from the Italian Haemophilia Register relevant to clinical practice. Br J Obstet Gynaecol. 2003;110(3):311-314. (Pubitemid 36298918)
17. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17(19):2265-2281.
18. Parsons LS. Reducing bias in a propensity score-matched-pair sample using greedy matching techniques. Proceedings of the Twenty-Sixth Annual SAS Users Group International Conference. Cary, NC: SAS Institute; 2004.
19. Pencina MJ, D'Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med. 2004;23(13):2109-2123. (Pubitemid 38968032)
20. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27(2):157-172; discussion 207-212.
21. Franchini M, Veneri D, Lippi G, Stenner R. The efficacy of rituximab in the treatment of inhibitor-associated hemostatic disorders. Thromb Haemost. 2006;96(2):119-125. (Pubitemid 44219376)
22. Schwartz RS, Gabriel DA, Aledort LM, Green D, Kessler CM. A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gammaglobulin. Blood. 1995;86(2):797-804.
23. Collins P, Baudo F, Huth-Kuhne A, et al. First line immunosuppressive treatment for acquired factor VIII antibodies: results of the European Acquired Haemophilia registry (EACH2) [abstract]. J Thromb Haemost. 2009;7(Suppl 2):Abstract PP-MO-609.